Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mycology

Cryptococcus neoformans Isolates from Transplant Recipients Are Not Selected for Resistance to Calcineurin Inhibitors by Current Immunosuppressive Regimens

Jill R. Blankenship, Nina Singh, Barbara D. Alexander, Joseph Heitman
Jill R. Blankenship
1Departments of Molecular Genetics and Microbiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Singh
2Division of Infectious Diseases, Pittsburgh Veterans Affairs Medical Center, Pittsburgh, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara D. Alexander
3Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Heitman
1Departments of Molecular Genetics and Microbiology
3Medicine
4Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: heitm001@duke.edu
DOI: 10.1128/JCM.43.1.464-467.2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The immunosuppressants tacrolimus (FK506) and cyclosporine A inhibit calcineurin and have potent antifungal activity. In this study, 24% of Cryptococcus neoformans isolates from solid-organ transplant patients exhibited altered sensitivity to these drugs, which may have an impact on the infectious course but does not appear to be the consequence of immunosuppressive therapy.

Invasive fungal infections occur in up to 40% of organ transplant patients and are often difficult to treat (28). Advancements in therapy such as fluconazole prophylaxis have decreased fungal infections (33), but fluconazole-resistant fungal species and Cryptococcus neoformans infections, which often occur late after discontinuation of fluconazole prophylaxis (11), remain problematic. C. neoformans risk factors in transplant patients are poorly understood, and prognosis is difficult to assess (7, 30, 37). This may be attributable to the low relative risk of cryptococcosis in transplant recipients (1 to 3%), nonstandardized treatment regimens, and prolonged intervals between onset and diagnosis (17, 20).

Data concerning well-known risk factors for cryptococcosis from the human immunodeficiency virus (HIV) field may provide some insights relevant to transplant settings; however, determining the effect of therapy-induced immunosuppression on this pathogen is essential to understanding pathogenesis and epidemiology in transplant populations. Although the relative risk of C. neoformans infection in transplant patients is low, the attributable mortality rate of up to 45% (16-18) highlights a need to better understand and control this infectious malady.

The immunosuppressants cyclosporine A (CsA) and tacrolimus (FK506) are mainstays of immunosuppressive therapy. CsA and FK506 bind to the immunophilins cyclophilin A and FKBP12, respectively, and these complexes inhibit the protein phosphatase calcineurin (5, 13, 15, 20, 25, 26). In humans, calcineurin is required for T-cell activation in response to antigen presentation, and its inhibition suppresses immune responses and reduces transplanted organ rejection (8, 14, 27). Calcineurin is also an important signaling molecule in fungal cell wall maintenance, responses to cation stress, pheromone response, and, in C. neoformans, growth at 37°C and virulence (4, 9, 13, 23, 24, 25, 34, 36). CsA and FK506 inhibit fungal calcineurin and exert broad antifungal effects, either alone or in combination with other antifungal drugs (3, 32).

Immunosuppressive treatment alters the course of cryptococcal infection in animal models and may also affect infection of human transplant recipients (17). CsA can clear C. neoformans pulmonary infections in a murine model of infection, although CsA exacerbates cryptococcal meningitis in rabbits via immunosuppression and failure to cross the blood-brain barrier (22, 29). A retrospective study showed cryptococcal infections in patients receiving FK506 less commonly involve the central nervous system, a hallmark of cryptococcosis (17). This may be attributable to both FK506 antifungal activity and its unique ability to cross the blood-brain barrier (25, 32). Cryptococcosis in solid-organ transplant recipients provides an ideal system in which to test if immunosuppressive treatments also have antifungal activity in vivo. Here we examined what effect immunosuppressive treatment has on C. neoformans strains infecting solid-organ transplant recipients. As a control, isolates from transplant recipients were compared to 17 isolates from HIV-infected patients not exposed to immunosuppressants.

Thirty-three clinical isolates typed as C. neoformans were collected from 30 organ transplant recipients at several transplant centers around the world (Table 1). Based on carbohydrate assimilation profiles (bioMérieux), all 33 strains and the control strain H99 typed as C. neoformans. Analysis of the MAT-encoded STE20 gene (primers available upon request) and mating assays identified most isolates as serotype A MATα (Table 1). By serotyping of capsular antigen with a cell agglutination kit (Iatron), all isolates (except PAT8ISO1 and PAT12ISO1) were serotype A, confirming the PCR results. PAT12ISO1 typed as serotype B, and PAT8ISO1 was untypeable. In summary, all clinical strains tested were serotype A MATα with the exception of PAT12ISO1, a serotype B MATα variety C. gattii isolate.

The clinical strains were assayed for production of known virulence traits. Each strain tested, including strains from both HIV-infected subjects and transplant recipients, produced both urease and melanin, with some modest differences in melanin production. Urease production was assayed by suspending colonies in 1 ml of distilled H2O in the presence of a BBL urease differentiation disk (Becton Dickinson & Co.) for 6 h at room temperature. Melanin production was assessed by spotting ≈106 cells onto Niger seed agar medium at 30°C. Although some variation in melanin production was noted at 24 h, most strains appeared to approach wild-type levels of melanin production by 48 h. While it is clear that strains unable to produce melanin are less virulent (reviewed in reference 19), there is no indication that more subtle differences in melanin production have a clinical impact. There were also measurable differences in the ability of the clinical strains from transplant patients to produce capsule, measured by growing cells on solid Dulbecco's modified Eagle's medium (2), resuspending them in phosphate-buffered saline, and visualizing capsule with India ink (Table 1). Mutations in capsule genes attenuate virulence (6). However, modest variations in capsule production among nonisogenic strains are not correlated with altered virulence (10, 21).

Serotype A strains of C. neoformans are sensitive to growth inhibition by calcineurin inhibitors at 37 to 39°C (26). Here, we tested the susceptibility of the clinical isolates to CsA and FK506. Isolates from transplant patients and HIV-infected subjects were serially diluted onto YPD rich medium (31) with or without 100 μg of CsA or 1 μg of FK506 per ml at 35°C and observed for growth at each dilution. Most strains, including the control strain H99, proliferated in the presence of either calcineurin inhibitor at this temperature. However, several of the clinical strains, including PAT6ISO1, PAT8ISO1, PAT10ISO1, PAT22ISO1, and PAT28ISO1, were unable to grow on media containing FK506 or CsA at this temperature, indicating a requirement for calcineurin activity at lower temperatures in these clinical isolates (Fig. 1A and data not shown). This hypersensitivity was observed with clinical isolates from both transplant and HIV-infected patients, and thus the drug hypersensitivity represents natural variation in the population and is unrelated to drug exposure in vivo.

Mutations increasing drug susceptibility could occur in downstream calcineurin targets or parallel pathways that render calcineurin essential at lower temperatures. Strains that lack Cts1 or the small G protein Ras1 are temperature sensitive and hypersensitive to calcineurin inhibitors (1, 12). Mutations in these genes could contribute to calcineurin inhibitor hypersensitivity in the patient population. Indeed, three hypersensitive strains (PAT6ISO1, PAT8ISO1, and PAT10ISO1) also exhibit temperature-sensitive growth (data not shown).

Interestingly, C. neoformans strains hypersensitive to calcineurin inhibitors are negatively correlated with cerebrospinal fluid infection. Only one of the five hypersensitive strains was isolated from the cerebrospinal fluid, compared to a rate of over 60% cerebrospinal fluid involvement for all strains, and at least four of these five patients received FK506. Thus, strains naturally hypersensitive to FK506 and CsA appear less likely to establish a cerebrospinal fluid infection, and FK506 may have an even greater beneficial effect in patients infected with these strains.

The purpose of this study was to test if the calcineurin inhibitors used for immunosuppression exhibit enough antifungal activity in vivo to select resistant C. neoformans isolates. Strains from transplant and HIV patients were compared for sensitivity to CsA and FK506 at 38°C. Most strains were able to grow on medium lacking drugs at this temperature, but only three of the strains from transplant patients (PAT24ISO1, PAT26ISO1, and PAT27ISO1) (9%) grew on media containing either CsA (100 μg/ml) or FK506 (1 μg/ml) at 38°C (Fig. 1B). Mutant strains lacking FKBP12 (MCC1) or expressing a dominant calcineurin A mutation, Cna1-1, which fails to bind the cyclophilin A-CsA complex (strain MCC11), were resistant to FK506 and CsA, respectively, but the wild-type control strain, H99, was not able to grow in the presence of either drug at 38°C (Fig. 1B and data not shown). More than 35% (6 of 17) of the strains from HIV-positive patients who had not received any form of immunosuppressive treatment demonstrated some resistance to calcineurin inhibitors (data not shown). When the entire CNB1 gene, encoding calcineurin B, and the CsA-cyclophilin/FK506-FKBP12 binding region of the CNA1 gene, encoding calcineurin A, were amplified and sequenced from the resistant isolates from the transplant recipients, no missense mutations were detected.

Resistance to calcineurin inhibitors is understood at a molecular level. A loss-of-function mutation in the drug-binding immunophilin protein or a mutation in the immunophilin drug binding site of one of the immunophilins or calcineurin A or B confers CsA and FK506 resistance. The resistant isolates identified here are, however, resistant to both drugs, and it is unlikely that resistant strains harbor double mutations in the genes encoding FKBP12 and cyclophilin A. Also, no mutations were found in the drug binding regions of the known target proteins. Furthermore, these strains are sensitive to rapamycin and fluconazole (data not shown), suggesting that resistance to calcineurin inhibitors may not be due to drug efflux pump induction. Resistance could be due to induction of a downstream effector of calcineurin signaling or to changes in several genes, similar to the panel of fluconazole-resistant C. albicans strains described by White (35).

Why are resistant isolates not selected? Guidelines for therapy suggest a concentration that, at least in the bloodstream, is consistent with the concentration of FK506 and CsA necessary to block C. neoformans growth under some in vitro conditions. Furthermore, the fungi were exposed to various concentrations of drug in the human host, which should enhance the selection of resistant isolates. Thus, C. neoformans must somehow escape drug activity, possibly by residing in tissues where the concentrations are not high enough to inhibit growth or within cells, such as macrophages, where they could be protected from antifungal action. Although our observations suggest that the current levels of CsA and FK506 used for patients do not have a sufficient antifungal effect against C. neoformans to select resistance, future studies will address the role that these immunosuppressive and antifungal drugs may have in Aspergillus or Candida infections and in altering the spectrum of cryptococcal infection in the transplant population.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Drug-hypersensitive and -resistant C. neoformans clinical isolates. (A) Some clinical isolates are hypersensitive to calcineurin inhibitors. Fivefold serial dilutions (starting at ≈10,000 cells) of wild-type strain H99, PAT6ISO1, PAT8ISO1, PAT10ISO1, and PAT22ISO1 were grown on YPD solid medium with no drug (−), 100 μg of CsA per ml, or 1 μg of FK506 per ml for 48 h at 30 or 35°C. (B) Several clinical isolates are resistant to calcineurin inhibitors. Wild-type strain H99, CNA1-1 mutant strain MCC11, and clinical isolates PAT24ISO1, PAT26ISO1, and PAT27ISO1 were diluted as in panel A and grown on YPD solid medium with no drug (−), 100 μg of CsA per ml, or 1 μg of FK506 per ml for 48 h at 30 or 38°C.

View this table:
  • View inline
  • View popup
TABLE 1.

Clinical strain data

ACKNOWLEDGMENTS

We thank Yong-Sun Bahn, Peter Kraus, John Perfect, and Andy Alspaugh for comments.

These studies were supported by R01 grants AI054719-01 (N.S.) and AI50438 (J.H.), the Howard Hughes Medical Institute, and the Burroughs Wellcome Fund.

FOOTNOTES

    • Received 28 June 2004.
    • Returned for modification 10 August 2004.
    • Accepted 15 September 2004.
  • Copyright © 2005 American Society for Microbiology

REFERENCES

  1. 1.↵
    Alspaugh, J. A., L. M. Cavallo, J. R. Perfect, and J. Heitman. 2000. RAS1 regulates filamentation, mating and growth at high temperature of Cryptococcus neoformans. Mol. Microbiol.36:352-365.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Bahn, Y. S., J. K. Hicks, S. S. Giles, G. M. Cox, and J. Heitman. 2004. Adenylyl cyclase-associated protein Aca1 regulates virulence and differentiation of Cryptococcus neoformans via the cyclic AMP-protein kinase A cascade. Eukaryot. Cell3:1476-1491.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Blankenship, J. R., W. J. Steinbach, J. R. Perfect, and J. Heitman. 2003. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr. Opin. Investig. Drugs4:192-199.
    OpenUrlPubMed
  4. 4.↵
    Breuder, T., C. S. Hemenway, N. R. Movva, M. E. Cardenas, and J. Heitman. 1994. Calcineurin is essential in cyclosporin A- and FK506-sensitive yeast strains. Proc. Natl. Acad. Sci. USA91:5372-5376.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Cardenas, M. E., R. S. Muir, T. Breuder, and J. Heitman. 1995. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J.14:2772-2783.
    OpenUrlPubMedWeb of Science
  6. 6.↵
    Chang, Y. C., and K. J. Kwon-Chung. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol. Cell. Biol.14:4912-4919.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Chuck, S. L., and M. A. Sande. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med.321:794-799.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Clipstone, N. A., and G. R. Crabtree. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature357:695-697.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Cruz, M. C., R. A. L. Sia, M. Olson, G. M. Cox, and J. Heitman. 2000. Comparison of the roles of calcineurin in physiology and virulence in serotype D and serotype A strains of Cryptococcus neoformans. Infect. Immun.68:982-985.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Dykstra, M. A., L. Friedman, and J. W. Murphy. 1977. Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect Immun.16:129-135.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Fishman, J. A., and R. H. Rubin. 1998. Infection in organ-transplant recipients. N. Engl. J. Med.338:1741-1751.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    Fox, D. S., G. M. Cox, and J. Heitman. 2003. Phospholipid-binding protein Cts1 controls septation and functions coordinately with calcineurin in Cryptococcus neoformans. Eukaryot. Cell.2:1025-1035.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Fox, D. S., M. C. Cruz, R. A. Sia, H. Ke, G. M. Cox, M. E. Cardenas, and J. Heitman. 2001. Calcineurin regulatory subunit is essential for virulence and mediates interactions with FKBP12-FK506 in Cryptococcus neoformans. Mol. Microbiol.39:835-849.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Fruman, D. A., C. B. Klee, B. E. Bierer, and S. J. Burakoff. 1992. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc. Natl. Acad. Sci. USA89:3686-3690.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Hemenway, C. S., and J. Heitman. 1999. Calcineurin: structure, function, and inhibition. Cell. Biochem. Biophys.30:115-151.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Hooper, D. C., A. A. Pruitt, and R. H. Rubin. 1982. Central nervous system infection in the chronically immunosuppressed. Medicine (Baltimore)61:166-188.
    OpenUrlPubMed
  17. 17.↵
    Husain, S., M. M. Wagener, and N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis.7:375-381.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Jabbour, N., J. Reyes, S. Kusne, M. Martin, and J. Fung. 1996. Cryptococcal meningitis after liver transplantation. Transplantation61:146-149.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Jacobson, E. S. 2000. Pathogenic roles for fungal melanins. Clin. Microbiol. Rev.13:708-717.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    Kong, N. C., W. Shaariah, Z. Morad, A. B. Suleiman, and Y. H. Wong. 1990. Cryptococcosis in a renal unit. Aust. N. Z. J. Med.20:645-649.
    OpenUrlPubMed
  21. 21.↵
    Littman, M. L., and E. Tsubura. 1959. Effect of degree of encapsulation upon virulence of Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med.101:773-777.
    OpenUrl
  22. 22.↵
    Mody, C. H., G. B. Toews, and M. F. Lipscomb. 1989. Treatment of murine cryptococcosis with cyclosporin-A in normal and athymic mice. Am. Rev. Respir. Dis.139:8-13.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Moser, M. J., J. R. Geiser, and T. N. Davis. 1996. Ca2+-calmodulin promotes survival of pheromone-induced growth arrest by activation of calcineurin and Ca2+-calmodulin-dependent protein kinase. Mol. Cell. Biol.16:4824-4831.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Nakamura, T., Y. Liu, D. Hirata, H. Namba, S.-i. Harada, T. Hirokawa, and T. Miyakawa. 1993. Protein phosphatase type 2B (calcineurin)-mediated, FK506-sensitive regulation of intracellular ions in yeast is an important determinant for adaptation to high salt stress conditions. EMBO J.12:4063-4071.
    OpenUrlPubMedWeb of Science
  25. 25.↵
    Odom, A., S. Muir, E. Lim, D. L. Toffaletti, J. Perfect, and J. Heitman. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J.16:2576-2589.
    OpenUrlAbstract
  26. 26.↵
    Odom, A., M. D. Poeta, J. Perfect, and J. Heitman. 1997. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob. Agents Chemother.41:156-161.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    O'Keefe, S. J., J. i. Tamura, R. L. Kincaid, M. J. Tocci, and E. A. O'Neill. 1992. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature357:692-694.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Paya, C. V. 1993. Fungal infections in solid-organ transplantation. Clin. Infect. Dis.16:677-688.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    Perfect, J. R., and D. T. Durack. 1985. Effects of cyclosporine in experimental cryptococcal meningitis. Infect. Immun.50:22-26.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Saag, M. S., W. G. Powderly, G. A. Cloud, P. Robinson, M. H. Grieco, P. K. Sharkey, S. E. Thompson, A. M. Sugar, C. U. Tuazon, J. F. Fisher, et al. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med.326:83-89.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    Sherman, F. 1991. Getting started with yeast. Methods Enzymol.194:3-21.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Singh, N., and J. Heitman. 2004. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation77:795-800.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    Singh, N., and S. Husain. 2000. Infections of the central nervous system in transplant recipients. Transpl. Infect. Dis.2:101-111.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Stathopoulos, A. M., and M. S. Cyert. 1997. Calcineurin acts through the CRZ1/TCN1-encoded transcription factor to regulate gene expression in yeast. Genes Dev.11:3432-3444.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother.41:1482-1487.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    Withee, J. L., J. Mulholland, R. Jeng, and M. S. Cyert. 1997. An essential role of the yeast pheromone-induced Ca2+ signal is to activate calcineurin. Mol. Biol. Cell8:263-277.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    Zuger, A., E. Louie, R. S. Holzman, M. S. Simberkoff, and J. J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann. Intern. Med.104:234-240.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Cryptococcus neoformans Isolates from Transplant Recipients Are Not Selected for Resistance to Calcineurin Inhibitors by Current Immunosuppressive Regimens
Jill R. Blankenship, Nina Singh, Barbara D. Alexander, Joseph Heitman
Journal of Clinical Microbiology Jan 2005, 43 (1) 464-467; DOI: 10.1128/JCM.43.1.464-467.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cryptococcus neoformans Isolates from Transplant Recipients Are Not Selected for Resistance to Calcineurin Inhibitors by Current Immunosuppressive Regimens
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cryptococcus neoformans Isolates from Transplant Recipients Are Not Selected for Resistance to Calcineurin Inhibitors by Current Immunosuppressive Regimens
Jill R. Blankenship, Nina Singh, Barbara D. Alexander, Joseph Heitman
Journal of Clinical Microbiology Jan 2005, 43 (1) 464-467; DOI: 10.1128/JCM.43.1.464-467.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Calcineurin Inhibitors
Cryptococcus neoformans
Cyclosporine
Drug Resistance, Fungal
Immunosuppressive Agents
Organ Transplantation
Tacrolimus

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X